| Abstrakt: |
A study conducted by Yale University School of Medicine examined the time to cancer treatment initiation and relative dose intensity (RDI) of chemotherapy for patients with breast cancer living with HIV. The study found that patients with breast cancer and HIV may experience reduced adjuvant chemotherapy RDI, resulting in greater dose reductions, delays, or discontinuation. The research suggests that strategies to support this vulnerable population during chemotherapy treatment are necessary. The study highlights the importance of addressing the unique needs of patients with breast cancer and comorbid HIV to improve outcomes. [Extracted from the article] |
